Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.38 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17788654 | 1.00 | HTT (0.43) | HTTMAPKAPK2ALDH1A1KDM4ENPC1 | |
| SCHEMBL12201542 | 1.00 | HTT (0.43) | HTTMAPKAPK2ALDH1A1KDM4ENPC1 | |
| SCHEMBL14301371 | 0.80 | KDM4E (0.42) | HTTMAPKAPK2ALDH1A1KDM4ENPC1 | |
| SCHEMBL8259486 | 0.80 | SMN1; SMN2 (0.39) | KDM4EKMT2AMEN1SLC6A3CACNA1F | |
| SCHEMBL8254526 | 0.80 | SMN1; SMN2 (0.39) | KDM4EKMT2AMEN1SLC6A3CACNA1F | |
| SCHEMBL10315775 | 0.80 | SMN1; SMN2 (0.39) | KDM4EKMT2AMEN1SLC6A3CACNA1F | |
| SCHEMBL17788651 | 0.78 | SLC6A3 (0.50) | ADRB2SLC6A3CACNA1FCHRM2CHRM1 | |
| SCHEMBL17788614 | 0.78 | SLC6A3 (0.50) | ADRB2SLC6A3CACNA1FCHRM2CHRM1 | |
| SCHEMBL10058171 | 0.78 | AKT1 (0.50) | ALDH1A1KMT2ALMNAMEN1ADRB2 | |
| SCHEMBL17788650 | 0.78 | SLC6A3 (0.50) | ADRB2SLC6A3CACNA1FCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20130116169-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-05-09 | — | — | US | disclosed |
| US-8426359-B2 | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-04-23 | — | — | US | disclosed |
| US-7504391-B2 | Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders | SCHERING CORPORATION (US) | 2009-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116169-A1 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE | SERPINB1, PRSS1, SPINT2 | HTT 2643/4885MAPKAPK2 4439/4885ALDH1A1 2015/4885 |
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | DRD4, ADORA1, ADORA3 | HTT 292/4885MAPKAPK2 4001/4885ALDH1A1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.